



(51) International Patent Classification:

A61K 31/10 (2006.01)	A61P 1/00 (2006.01)
A61K 31/18 (2006.01)	A61P 11/00 (2006.01)
A61K 31/4418 (2006.01)	A61P 17/00 (2006.01)
A61K 31/445 (2006.01)	A61P 19/00 (2006.01)
A61K 31/496 (2006.01)	A61P 19/02 (2006.01)
A61K 31/519 (2006.01)	A61P 29/00 (2006.01)
A61K 39/395 (2006.01)	A61P 37/00 (2006.01)
A61K 45/06 (2006.01)	A61P 43/00 (2006.01)

(21) International Application Number:

PCT/EP2024/079212

(22) International Filing Date:

16 October 2024 (16.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2315822.3 16 October 2023 (16.10.2023) GB

(71) Applicant: **ISTESSO 3 LTD** [GB/GB]; 3 Pancras Square,
London N1C 4AG (GB).

(72) Inventors: **PATEL, Lisa**; Istesso Ltd, 3 Pancras Square,
London N1C 4AG (GB). **FOSTER, Martyn Leslie**; 45
Hope Road, Benfleet Essex SS7 5JQ (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ANTI-FIBROTIC COMBINATION THERAPEUTICS




Figure 10

(57) Abstract: The invention provides combination therapies comprising anti-fibrotic compounds and mitochondrial complex I mod-
ulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders associated with fibrosis,
such as idiopathic pulmonary fibrosis, interstitial lung disease, liver and kidney diseases, IBD, and RA.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*